US Food and Drug Administration officials may allow some wiggle room with the coronavirus vaccine safety recommendations that garnered the ire from the White House in recent days.
The expectation for a vaccine candidate to be considered for an emergency use authorization is that Phase III clinical trials include a median of two months of safety follow-up
“We're flexible. We're not going to be completely flexible,” Marks said during a 5 October Journal of the American Medical Association event